A Randomized, Blinded, Placebo-Controlled, Two-Part, Phase 2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of YB-101 in Participants With Graves' Disease
Status: Recruiting
Location: See all (29) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body. The study consists of a part 1, blinded treatment period, and a part 2 double-blinded treatment period. Participants will receive YB-101 or Placebo subcutaneously. Participants who participate in Part 1 can not participate in Part 2. Participants will complete 34-39 in-clinic visits in Part 1 or Part 2 over an approximate 40 week period.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Have a documented diagnosis of Graves' Disease confirmed by the presence of thyroid-stimulating hormone receptor antibodies (TRAbs) by medical history or screening laboratory assessment
• Have a pre-existing diagnosis of TED or, conversely, no evidence of TED at the ophthalmological examination performed during screening
• Additional inclusion criteria are defined in the protocol
Locations
United States
Arizona
Site 112
RECRUITING
Gilbert
Site 130
NOT_YET_RECRUITING
Phoenix
Site 132
RECRUITING
Tucson
California
Site 121
RECRUITING
La Mesa
Site 103
NOT_YET_RECRUITING
Sacramento
Site 111
NOT_YET_RECRUITING
San Francisco
Site 105
RECRUITING
Torrance
Florida
Site 109
RECRUITING
Miami Lakes
Site 115
RECRUITING
Palm Harbor
Site 123
NOT_YET_RECRUITING
Sarasota
Georgia
Site 118
RECRUITING
Macon
Kentucky
Site 122
RECRUITING
Bowling Green
Michigan
Site 126
RECRUITING
Flint
Site 107
RECRUITING
Livonia
North Carolina
Site 131
RECRUITING
Cary
Nebraska
Site 108
RECRUITING
Omaha
New York
Site 129
RECRUITING
Niagara Falls
Site 120
RECRUITING
Orchard Park
Pennsylvania
Site 124
NOT_YET_RECRUITING
Sayre
Texas
Site 100
RECRUITING
Amarillo
Site 117
RECRUITING
Conroe
Site 133
RECRUITING
Dallas
Site 128
RECRUITING
Edinburg
Site 127
RECRUITING
El Paso
Site 106
RECRUITING
Fort Worth
Site 110
RECRUITING
Houston
Site 101
RECRUITING
Humble
Other Locations
Australia
Site 151
NOT_YET_RECRUITING
East Melbourne
Site 150
NOT_YET_RECRUITING
Melbourne N.
Contact Information
Primary
Victoria Lacasse, MD
VL@YarrowBioscience.com
469-278-6161
Time Frame
Start Date:2026-06-10
Estimated Completion Date:2029-09
Participants
Target number of participants:232
Treatments
Experimental: YB-101
In Part 1, participants will receive YB-101 via subcutaneous injection. Part 2 participants will receive YB-101 via subcutaneous injection.
Placebo_comparator: Placebo YB-101
In Part 1, participants will receive placebo via subcutaneous injection. Part 2 participants will receive placebo via subcutaneous injection.